← FDA DRUG APPROVALS

FDA ANDA · ANDA209665

CISATRACURIUM BESYLATE

Sponsor: EUGIA PHARMA

APPLICATION
ANDA209665
TYPE
ANDA
ORIGINAL APPROVAL
2020-10-27
LATEST ACTION
2020-10-27
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CISATRACURIUM BESYLATE PRESERVATIVE FREEDiscontinued
CISATRACURIUM BESYLATE EQ 2MG BASE/ML · INJECTABLE · INJECTION

Approval history

2020-10-27UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →